Table 1.
Baseline characteristics of patients according to the presence/absence of HT and neurological outcomes at 3 months.
| Characteristics | Without-HT (n = 160) | With-HT (n = 98) | p | Favorable outcome (n = 115) | Unfavorable outcome (n = 143) | p |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age, years, median (IQR) | 70(61, 79) | 71(61.8, 79) | 0.854 | 70(62, 78) | 71(61, 80) | 0.722 |
| Sex, men, % | 101(63.1%) | 55(56.1%) | 0.264 | 69(60.0%) | 87(60.8%) | 0.891 |
| Risk factors | ||||||
| Smoking, % | 52(32.5%) | 27(27.6%) | 0.403 | 33(28.7%) | 46(32.2%) | 0.548 |
| Drinking, % | 29(18.1%) | 14(14.3%) | 0.422 | 20(17.4%) | 23(16.1%) | 0.779 |
| Hypertension, % | 95(59.4%) | 62(63.3%) | 0.534 | 65(56.5%) | 92(64.3%) | 0.201 |
| Diabetes, % | 38(23.8%) | 21(21.4%) | 0.667 | 22(19.1%) | 37(25.9%) | 0.200 |
| Stroke history, % | 16(10.0%) | 15(15.3%) | 0.210 | 10(8.7%) | 21(14.7%) | 0.136 |
| Atrial fibrillation, % | 74(46.3%) | 50(51.0%) | 0.485 | 52(45.2%) | 72(50.5%) | 0.450 |
| Coronary heart disease, % | 66(41.3%) | 47(48.0%) | 0.292 | 47(40.9%) | 66(46.2%) | 0.395 |
| Clinical data | ||||||
| Systolic BP (mmHg), median (IQR) | 145.5(128, 162.8) | 142.5(128, 172.3) | 0.618 | 142(127, 160) | 146(130, 170) | 0.205 |
| Diastolic BP (mmHg), median (IQR) | 80(71.3, 90) | 80(73, 95.8) | 0.240 | 80(72, 90) | 80(73, 94) | 0.230 |
| Admission NIHSS, median (IQR) | 14(9,19) | 14(11,18) | 0.463 | 13(8,18) | 15(12, 19) | 0.003 |
| Time from onset to recanalization (minutes), median (IQR) | 414(281.5, 600) | 387.5(307.8, 607) | 0.962 | 390(270, 572) | 410(304, 628) | 0.442 |
| Time from arrival to recanalization (minutes), median (IQR) | 206.5(148.3, 273.8) | 219.5(179, 275) | 0.090 | 218(155, 270) | 209(167, 275) | 0.938 |
| Prior IVT, % | 57(35.6%) | 31(31.3%) | 0.511 | 40(34.8%) | 48(33.6%) | 0.838 |
| ASPECTS, median (IQR) | 9(9,9) | 7 (6,8) | < 0.001 | 9(8,9) | 8(7,9) | < 0.001 |
| Recanalization (mTICI ≥2b), % | 142(88.8%) | 23(23.5%) | < 0.001 | 95(82.6%) | 70(49.0%) | < 0.001 |
| Procedural modes | 0.717 | 0.472 | ||||
| Stent retriever only | 65(40.6%) | 44(44.9%) | 51(44.3%) | 58(40.6%) | ||
| Stent retriever with rescue therapy | 53(33.1%) | 28(28.6%) | 38(33.0%) | 43(30.1%) | ||
| Other modes without stent retriever | 42(26.3%) | 26(26.5%) | 26(22.6%) | 42(29.4%) | ||
| Occlusion site, % | 0.084 | < 0.001 | ||||
| ICA | 56(35.0%) | 22(22.4%) | 49(42.6%) | 29(20.3%) | ||
| MCA | 77(48.1%) | 53(54.1%) | 49(42.6%) | 81(56.6%) | ||
| Tandem occlusion | 27(16.9%) | 23(23.5%) | 17(14.8%) | 33(23.1%) | ||
| Cause (TOAST), % | 0.082 | 0.255 | ||||
| LAA | 83(51.9%) | 37(37.8%) | 60(52.2%) | 60(42.0%) | ||
| CE | 44(27.5%) | 33(33.7%) | 30(26.1%) | 47(32.9%) | ||
| Other | 33(20.6%) | 28(28.6%) | 25(21.7%) | 36(25.2%) | ||
| Laboratory data | ||||||
| Blood glucose, mmol/L, median (IQR) | 6.9(5.9, 8.7) | 7.2(5.6, 9.2) | 0.935 | 6.7(5.6, 8.1) | 7.2(5.8, 9.5) | 0.120 |
| Platelet1, × 109/L, median (IQR) | 194(159.3, 235.5) | 190.5(156.3, 227.3) | 0.418 | 195(167, 238) | 188(149, 228) | 0.239 |
| Monocytes1, × 109/L, median (IQR) | 0.4(0.2, 0.6) | 0.4(0.2, 0.5) | 0.464 | 0.4(0.2, 0.6) | 0.4(0.2, 0.5) | 0.195 |
| Neutrophils1, × 109/L, median (IQR) | 7.0(4.6, 9.5) | 6.1(3.9, 8.4) | 0.035 | 6.6(4.2, 8.8) | 6.5(4.7, 9.0) | 0.721 |
| Lymphocytes1, × 109/L, median (IQR) | 1.2(0.8, 1.7) | 1.3(0.7, 2.0) | 0.623 | 1.3(0.9, 1.8) | 1.2(0.7, 1.9) | 0.297 |
| NLR1, median (IQR) | 5.8(2.8, 10.8) | 4.7(2.2, 10.1) | 0.211 | 4.9(2.5, 8.9) | 5.7(2.4, 12.2) | 0.315 |
| Platelet2, × 109/L, median (IQR) | 193(158, 235) | 184(153, 221.5) | 0.252 | 193(157, 236) | 185(154, 220) | 0.142 |
| Monocytes2, × 109/L, median (IQR) | 0.5(0.2, 0.8) | 0.6(0.3, 0.8) | 0.164 | 0.6(0.3, 0.7) | 0.5(0.1, 0.8) | 0.191 |
| Neutrophils2, × 109/L, median (IQR) | 8.2(6.1, 10.4) | 9.7(8.3, 11.9) | < 0.001 | 7.5(6.0, 9.6) | 9.7(8.4, 11.9) | < 0.001 |
| Lymphocytes2, × 109/L, median (IQR) | 1.1(0.8, 1.5) | 0.8(0.6, 1.0) | < 0.001 | 1.2(0.9, 1.7) | 0.8(0.6, 1.0) | < 0.001 |
| NLR2, median (IQR) | 8.0(5.1, 10.7) | 12.2(9.9, 15.8) | < 0.001 | 6.7(4.1, 8.6) | 11.7(10.0, 15.5) | < 0.001 |
HT, hemorrhagic transformation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke scale; IVT, intravenous thrombolysis; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; TOAST, Trial of Org 10 172 in acute stroke treatment; ICA, internal carotid artery; MCA, middle cerebral artery; LAA, large-artery atherosclerosis; CE, cardioembolism; TICI, thrombolysis in cerebral infarction; NLR1, neutrophil-to-lymphocyte ratio before thrombectomy; NLR2, neutrophil-to-lymphocyte ratio after thrombectomy immediately. Significant P-values (p < 0.05) are marked in bold.